ESPR
Esperion Therapeutics, Inc.
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$3.18+0.00%
Price as of Jul 14, 2026
ESPR valuation
Esperion Therapeutics, Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- 50.21x
- P/E 2026E
- 18.48x
- P/E 2027E
- 14.58x
- P/E 2028E
- 4.05x
- P/S forward
- 3.90x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -2.66x
- Price / sales
- 1.96x
- Price / cash flow
- -45.01x
Enterprise value
- Enterprise value
- $1.2B
- EV / sales
- 2.88x
- EV / EBITDA
- 30.23x
- EV / EBIT
- 15.92x
- Market cap
- $818.6M
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.